To evaluate the cost-effectiveness of using a surgery, such as transurethral resection of the prostate (TURP) or photoselective vaporisation of the prostate using greenlight laser (GL-PVP), as initial treatment for men with moderate-to-severe benign prostate hyperplasia (BPH) compared to the standard practice of using pharmacotherapy as initial treatment followed by surgery if symptoms do not resolve.
Introduction
BPH is a common non-cancerous enlargement of the prostate affecting up to 50% of men aged ≥50 years [1] . BPH can result in the development of LUTS that can interfere with a patient's daily activities and negatively affect their quality of life [2] .
The severity of BPH-related LUTS is commonly defined using the IPSS (score of 0-7, mild; 8-19, moderate; and 20-35, severe). Several treatment options exist for patients with BPH-LUTS depending on patient preference for treatment and symptom severity [3] .
Patients with bothersome, moderate-to-severe symptoms can start pharmacotherapy (e.g., a-adrenergic blockers [a-blocker] and/or 5a-reductase inhibitors , or combined therapy [a-blocker + 5-ARI]). These may not entirely resolve symptoms, and patients need to take them for the rest of their lives [3] . Patients with unresolved symptoms may subsequently need a surgery, such as TURP. A newer surgical alternative to TURP is photoselective vaporisation of the prostate using greenlight laser (GL-PVP). This is an outpatient procedure that has better perioperative safety and shorter hospitalisation time compared to TURP, and faster symptomatic improvement vs pharmacotherapy [4, 5] .
The objective of the present study was to evaluate the costeffectiveness of using a BPH surgery, such as TURP or GL-PVP, as initial treatment for men with moderate-to-severe BPH-LUTS compared to the standard practice of using pharmacotherapy as initial treatment followed by a BPH surgery if symptoms do not resolve.
Patients and Methods

Strategies
We evaluated the cost-effectiveness of pharmacotherapy (i.e., 5-ARI, a-blocker, 5-ARI + a-blocker) followed by delayed surgical therapy (i.e., GL-PVP or TURP) for patients who failed the initial treatment vs upfront surgical therapy (i.e., GL-PVP or TURP). In total, eight strategies were compared: (i) upfront GL-PVP; (ii) 5-ARI followed by delayed GL-PVP; (iii) a-blocker followed by delayed GL-PVP; (iv) combined therapy (5-ARI + a-blocker) followed by delayed GL-PVP; (v) upfront TURP; (vi) 5-ARI followed by delayed TURP; (vii) a-blocker followed by delayed TURP; (viii) combined therapy (5-ARI + a-blocker) followed by delayed TURP.
Target Population
The target population was men with a mean age of 65 years, with moderate-to-severe LUTS with presumed benign prostatic enlargement referred to a urologist with no presumed contraindications for medical or surgical therapy. The mean prostate volume of the patients in our hypothetical cohort was 53 mL, the mean IPSS was 16, and the mean PSA level was 3.8 ng/mL, based upon patient characteristics of referenced clinical trials. The baseline characteristics (i.e., start age, start IPSS, the slope of IPSS change by treatment type) were assigned to each simulated (hypothetical) patient at the start of each simulation by randomly sampling each baseline value from its respective distribution, as defined by the parameters provided in Table 1 .
Outcomes
The outcomes were discounted costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER).
Cost-Effectiveness Analysis
The cost-effectiveness analysis was performed from a public payer perspective and a lifetime horizon. All future costs and benefits were discounted at 1.5% annually for the lifetime of the cohort [6] . Cost-effectiveness was determined using a conventional willingness to pay threshold (k) of $50 000 (Canadian dollars)/QALY gained [6] .
Microsimulation Model
A microsimulation decision-analytic model was developed in TreeAge Pro 2018 (TreeAge Software Inc., Williamstown, MA, USA), to model the progression of BPH-LUTS and to project the costs and QALYs of the target population over their lifetime. A cycle length of 3 months was used, as it is the period over which symptoms and adverse events may resolve. A microsimulation sample size equating to 250 000 patients was determined empirically by running iterations of the model with 100 to >500 000 simulated individuals until model outputs stabilise.
At each cycle of the model, each simulated patient could progress or improve in IPSS, discontinue treatment, receive a surgery (TURP/GL-PVP), experience acute urinary retention (AUR) or other adverse events (e.g., dizziness, gynaecomastia, erectile dysfunction, ejaculatory dysfunction, incontinence, AUR, TUR syndrome, blood transfusion, bladder neck contracture or urethral stricture, and death from procedure), or die from other causes. The simulated patients progress stochastically through these temporary health states, given the clinical probabilities associated with each treatment option, and thus, they accumulate costs and utility weights related to each event. The clinical probabilities, costs and utilities used to populate the model were derived from the literature and are provided in the supplement. The basic conceptual model structure is provided in Fig. 1 .
For disease progression, we assumed that: (i) patients on pharmacotherapy progressed in IPSS given the average slope of IPSS change and its standard deviation (SD) for each pharmacotherapy option. IPSS progression estimates were obtained from a large randomised trial comparing the three pharmacotherapies with respect to the mean change in IPSS and the proportion of patients with a ≥4-point deterioration and >3-point improvement in IPSS over a 4-year follow-up period [7] ; (ii) patients that received TURP achieved on average a 73% decrease in IPSS relative to their pre-procedure score, based on results from a large published trial [8] ; (iii) for patients that received GL-PVP, IPSS was estimated using the mean difference in postprocedure IPSS for GL-PVP vs TURP, derived from the meta-analyses of several trials [5, 8] ; (iv) for patients that received a surgery, we assumed that symptoms were stable for a duration of 5-8 years after the procedure [9] [10] [11] [12] [13] , after that time, patients progressed in IPSS based on the natural history [14] ; (v) for patients that responded to pharmacotherapy, the maximum symptom improvement was achieved by~12-27 weeks of treatment and remained
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For treatment adherence, we assumed that: (i) patients who failed pharmacotherapy (with a <3 point improvement from baseline) by the first year of treatment initiation, discontinued treatment; and (ii) and that certain patients discontinued pharmacotherapy due to adverse events [7] .
For patients that do not respond to the upfront treatments (i.e., pharmacotherapy or surgery) or for those who relapse in terms of BPH symptoms at any time, we assumed that these patients would receive a subsequent BPH surgery within 2 years when the IPSS improvement remained <3 points from baseline [7, 8] . 
Data Sources
Clinical probabilities including clinical effectiveness with respect to IPSS improvement and the probability of adverse events were obtained from large randomised trials and metaanalyses [5, 7, 8, [15] [16] [17] [18] [19] . Clinical probabilities for patients that discontinue therapy were obtained from trials with a watchful-waiting arm [15] . The probability that patients on pharmacotherapy would require a surgical intervention, and the probability of receiving a second procedure or the probability of adverse events during the post-surgery period was obtained from studies with long-term follow-up periods [7, 20, 21] . Age-specific mortality was obtained from Statistics Canada. Clinical input parameters are listed in Table S1 .
BPH-LUTS-related health state utilities and the utility of adverse events were obtained from the literature. Utilities associated with BPH-LUTS severity were based on the Health Utilities Index â Mark 2 (Health Utilities Inc., Dundas, ON, Canada) and the utility associated with adverse events were derived using the standard gamble method [22, 23] . We assumed that the utility of bladder neck contracture and urethral stricture was the same as in previous models [22, 24] . For surgical procedures, a disutility associated with each procedure was applied to patients undergoing a BPH surgery, and a recovery period of 1 to 2 weeks for GL-PVP and 4 to 8 weeks for TURP was used in estimating the effect of surgeries on health-related quality of life. We used an additive approach to applying utilities to joint health states. Utility values are shown in Table S2 .
A public payer costing perspective was adopted. Perioperative costs associated with GL-PVP and TURP procedures were obtained from a retrospective cost analysis conducted between September 2013 and 30 September 2015 at the Toronto Western Hospital, Toronto, Ontario [25] . The costs of pharmacotherapy were obtained from the Ontario Drug Benefits programme formulary [26] . All other costs were collected from the literature. Certain adverse events (i.e., incontinence, erectile and ejaculatory dysfunction, gynaecomastia and dizziness) were assumed to result in an additional visit to a urologist. Where available Canadian sources were used. For non-Canadian sources, costs were converted to Canadian prices using purchasing power parity. All costs were inflated to the 2015 cost year using the consumer price index. Costs are shown in Table S3 .
Model Validation
The model was validated by comparing IPSS progression outputs (i.e., proportion of patients with >3-point improvement and ≥4-point progression in IPSS, and mean change in IPSS at 48 months of therapy) against published literature (Table S4 ). Figure 2 shows the mean change in IPSS over the cohort's lifetime for all eight strategies. Figure S1 displays the proportion of patients who require BPH surgery (one or more) over their lifetime for all eight strategies compared.
Sensitivity and Probabilistic Analyses
Scenario analysis was used to evaluate the effect of using multiplicative vs an additive approach for estimating utilities of joint health states and to estimate the impact of varying pharmacotherapy discontinuation rates. Threshold analysis was performed to evaluate the impact of the presumed duration over which BPH symptoms were assumed to remain stable after surgery. Probabilistic analysis was used to evaluate parameter uncertainty using a two-dimensional Monte Carlo simulation of 250 iterations, with 200 000 simulated individuals, by randomly sampling input parameters from Beta distributions for clinical probabilities and utilities and Gamma distributions for costs at each iteration. The result of the probabilistic analysis is displayed using a costeffectiveness acceptability curve (CEAC). The CEAC for each strategy was generated by plotting the proportion of iterations where a given strategy displays the greatest net benefit [Net Benefit = QALY 9 k À Cost] at a given cost-effectiveness threshold (k), indicating the probability of cost-effectiveness when considering the uncertainty in all model input parameters simultaneously.
Results
Costs
Out of all strategies examined, upfront TURP was the most costly option ($12 973/person) followed by upfront GL-PVP ($11 959/person) ( Table 2) . Upfront a-blocker with delayed GL-PVP was the least costly strategy ($9807/person). On average, the upfront surgery strategies cost $1221 to $3155 more per person vs an upfront pharmacotherapy with delayed surgery option.
QALYs
In terms of QALYs, upfront TURP was the most effective option (15.35 QALYs) followed closely by upfront GL-PVP (15.31 QALYs), whilst upfront a-blocker with delayed GL-PVP was the least effective (15.08 QALYs) ( Table 2) . Generally, upfront BPH surgeries resulted in QALY gains of 0.12-0.27 per person compared to the upfront pharmacotherapy strategies.
Cost-Effectiveness Analysis
In the cost-effectiveness analysis, all upfront pharmacotherapy followed by delayed TURP strategies were dominated (Fig. 3) . Upon elimination of all dominated strategies, only five 882 © 2018 The Authors BJU International © 2018 BJU International strategies remained: (i) upfront a-blocker followed by delayed GL-PVP; (ii) upfront 5-ARI followed by delayed GL-PVP; (iii) upfront combined treatment followed by delayed GL-PVP; (iv) upfront GL-PVP and (v) upfront TURP.
Upfront GL-PVP cost $1700 more and resulted in an average gain of 0.12 QALYs compared to the next most effective strategy, which was upfront combined treatment followed by delayed GL-PVP (ICER: $14 069/QALY). Whilst, the most effective strategy, upfront TURP, cost $1015 more and resulted in only a small gain of~0.03 QALYs in comparison with the second most effective option, which was upfront GL-PVP (ICER: $29 066/QALY). The undiscounted ICERs were slightly lower (Table S5) .
Sensitivity Analysis
The use of a multiplicative approach for estimating utilities for joint health states resulted in slightly lower ICERs, with values of $22 869/QALY and $19 509/QALY with and without discounting, respectively, for upfront TURP vs upfront GL-PVP (Tables S6 and S7) . Similarly, the costeffectiveness findings were robust to the variation of discontinuation rates when this was varied over a large range (Fig. S2) .
Threshold Analysis
Threshold analysis indicated that upfront surgery options remained optimal when the presumed years of BPH symptom stability lasted for ≥1 year after surgery (Fig. S3) . When the presumed years of symptom stability after surgery lasted between 1 and 3 years, upfront GL-PVP was optimal, whereas for symptom stability lasting for ≥3 years, upfront TURP was the optimal strategy. However, when the symptom improvement persisted for <1 year after surgery, upfront combined therapy followed by GL-PVP became the optimal option.
Probabilistic Analysis
Based on the probabilistic analysis (Fig. 4) , compared to upfront pharmacotherapies, the upfront surgeries were more likely to be cost-effective at thresholds over~$15 000/QALY. Increasing thresholds generally favoured upfront TURP over upfront GL-PVP as the optimal strategy. At a conventional threshold of $50 000/QALY, the probability of costeffectiveness was 79% for all the upfront surgery options together (46% of upfront TURP, 33% of upfront GL-PVP) and 21% for upfront pharmacotherapy (<10% for each upfront pharmacotherapy option).
Discussion
We compared the cost-effectiveness of using a combination of surgical and pharmacotherapy strategies to manage BPH-LUTS in patients with bothersome, moderate-to-severe symptoms. Our analysis indicated that compared to upfront pharmacotherapy, upfront surgeries were more costly but also more effective. In addition, all pharmacotherapy strategies involving delayed TURP for those who fail initial therapy were dominated. Probabilistic analysis indicated that upfront surgery options produced the highest net benefit and probability of cost-effectiveness at willingness to pay thresholds over $15 000/QALY. Regarding the generalisability of our findings, our target population was men with a mean age of 65 years with bothersome, moderate-to-severe LUTS with presumed benign prostatic enlargement referred to a urologist with no presumed contraindications for medical or surgical therapy, and with no history of previous prostate or urethral surgeries or of prostate cancer. The mean prostate volume of the patients in our present hypothetical cohort was 53 mL, the mean IPSS was 16, and the mean PSA level was 3.8 ng/mL, based upon the patient characteristics of the referenced clinical trials.
Our results are similar to previous evaluations of BPH treatment in Canada. Bowen et al. [4] performed an observational patient level cost-effectiveness analysis of GL-PVP vs TURP involving 163 patients over a 6-month time horizon. This analysis found that GL-PVP cost $971 less and displayed a questionable gain of 0.007 QALYs vs TURP, indicating that GL-PVP has a cost-saving at a 6-month time horizon. Ismaila et al. [27] used a state transition model to compare the three pharmacotherapy options followed by delayed TURP based largely on data from the Combination of Avodart and Tamsulosin (CombAT) trial and found combined therapy to be the most cost-effective alternative.
Only one other older model, using a 5-year time horizon, compared pharmacotherapy to BPH surgery and found TURP to be less effective and more costly [28] .
Our present study is limited in several ways. First, data on clinical effectiveness and adverse events were mainly obtained either from randomised trials or meta-analyses of trials. Whilst randomised trials are the 'gold standard' for measuring clinical effectiveness, the study populations may not be representative of real-world patients with BPH-LUTS and adherence to long-term pharmacotherapy may be lower than presumed in our present model. Secondly, there is a lack of direct comparison of BPH surgery vs pharmacotherapy. In general, compared to pharmacotherapy trials, trials that compare surgical procedures tend to involve patients with slightly more advanced urinary symptoms; therefore, a network meta-analysis could help to obtain improved estimates of treatment effects. Finally, given the small difference in QALY gains associated with TURP vs GL-PVP, the ICER is likely to be influenced by the accuracy of estimates of treatment effects, costs, and the natural history of IPSS progression after surgery.
With respect to some of these limitations, we evaluated the impact of specific modelling assumptions through threshold and sensitivity analyses. These analyses indicated that upfront surgery options remained optimal when BPH symptom improvement lasted for as little as 1 year after surgery and under a wide range of pharmacotherapy discontinuation rates. However, we did not consider factors such as: (i) the possibility of treatment switching between classes of pharmacotherapy for those that failed the initial option; (ii) the cost of purchasing and maintenance of surgical technology; (iii) the risk preference of patients for an invasive surgery vs pharmacotherapy; (iv) the budget impact; and (v) the impact of withdrawal from concomitant mediation, such as anticoagulation or antiplatelet therapy, prior to TURP for patients with comorbid conditions. Furthermore, it is also important to note that a variety of additional surgical technologies are available for the treatment of BPH. Although we chose to compare the more common BPH surgeries, other laser-based options, such as holmium enucleation of the prostate (HoLEP), also exist [29, 30] . While HoLEP offers several clinical and economic benefits, particularly for patients with larger prostates, it is a technically more challenging procedure requiring a steep learning curve and a slightly longer operation time [29] [30] [31] [32] . These attributes have limited its widespread diffusion and the use of this procedure amongst urologists at the present time [29, 31] . However, future economic evaluations should also consider HoLEP, especially in relation to patient heterogeneity in terms of prostate size.
Our present study has several strengths. We evaluated multiple hypothetical strategies, we populated our model using recent meta-analyses and large trials of BPH treatment involving long-term follow-up such as the CombAT and GOLIATH (A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS TM Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia) trials. We also based our model on the underlying natural history of BPH and validated the model against published literature. Additionally, we performed probabilistic and threshold analyses to evaluate the impact of parameter uncertainty and key model assumptions. Our present results were robust to sensitivity analysis and indicated an~80% probability that an upfront BPH surgery would be the optimal treatment option at a conventional threshold of $50 000/QALY. Finally, our present study improves upon the current economic literature around BPH therapy by evaluating several plausible and hypothetical treatment strategies together and extending the time horizon over the lifetime through a modelling approach.
In conclusion, our results have important implications for existing practice. The analysis indicates that for 65-year-old patients with bothersome, moderate-to-severe BPH-LUTS (with prostate volume of 53 mL and IPSS of 16), the practice of using pharmacotherapy as initial treatment followed by delayed TURP for those who fail is less effective and more costly relative to newer therapeutic alternatives, and that using delayed GL-PVP instead of TURP for patients that fail initial pharmacotherapy is economically more attractive. Further, we found that the use of a BPH surgery as initial treatment for these patients is more cost-effective from the public payer perspective, with TURP being the optimal strategy followed closely by GL-PVP. However, given the shorter hospitalisation and recovery, and superior safety profile, GL-PVP could be considered the preferred surgical treatment modality compared to TURP, depending on patient preference. Likewise, whilst early surgical treatment maybe a rational choice, especially for patients who value prompt relief of symptoms, patients' preferences for treatment are likely to vary. As we could not fully incorporate individual preferences or risk attitudes into the model, the recommendations about patients as a whole may not correspond to the optimal treatment for a particular individual. Therefore, the health and economic evidence provided by our present model should be considered concurrently with patient preferences and risk attitudes in view of safety, recovery period, time to symptom relief, repeat operations, and the issue of concomitant medication and comorbid conditions.
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